| Range | 2.10 - 2.18 |
| 52 week | 1.44 - 3.53 |
| Open | 2.12 |
| Vol / Avg. | 427,348.00/451,721.00 |
| Mkt cap | 170.58M |
| P/E | - |
| Div/yield | - |
| EPS | -0.51 |
| Shares | 79.34M |
| Beta | 2.55 |
| Inst. own | 53% |
|
More events from DailyFinance »
|
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -7.52% | -26.29% |
| Operating margin | -5.04% | -24.75% |
| EBITD margin | - | 5.95% |
| Return on average assets | -4.34% | -17.31% |
| Return on average equity | -8.70% | -32.17% |
| Employees | 371 | - |
| Carbon Disclosure Rating | - | - |
| Stephen J. Fanning | Chairman of the Board, President, Chief Executive Officer | |
| John F. Glenn | Chief Financial Officer | |
| H. Daniel Ferrari | Vice President - Finance | |
| Doug W Heigel | Vice President - Operations | |
| Jeff C. Nardoci | Vice President - Global Marketing | |
| Lisa Parr | Vice President - Regulatory Affairs and Clinical Affairs | |
| Thomas J. Yorkey Ph.D. | Vice President - Research & Development | |
| Mark M. Sieczkarek | Lead Independent Director | |
| David B. Holthe CPA | Director | |
| Harold L. Covert | Independent Director |